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Abstract
Background: Diabetes mellitus (DM) affects tuberculosis (TB) treatment outcomes, mostly by increasing recurrence,
mortality and treatment failure. The objectives were to determine the pattern of change in glycosylated haemoglobin
(HbA1c) level in new TB patients admitted to hospital at the start and 3-months after TB treatment, and to relate the
measurements at these two time intervals to whether patients successfully completed treatment.
Methods: A prospective cohort study was conducted on hospitalized new TB patients at Masih Daneshvari Hospital
from 2012 to 2013. All patients were tested for HbA1c at the beginning and 3 months after initiation of TB treatment.
Changes in HbA1c were compared to TB treatment outcome.
Results: There were 317 new TB cases admitted to hospital of which 158 had HbA1c at baseline and 3-months. Of
these, 67 (42%) had normal values, 54 had an elevated HbA1c at either base-line or 3-months (uncertain diabetes status)
and 37 (24%) had elevated HbA1c (≥6.5%) at both time points (DM). There were differences between the groups: those
with DM were older, had a known history of DM and a higher prevalence of cavities on chest x-ray. There were 150
(95%) patients who successfully completed treatment with no significant differences between the groups.
Conclusion: There were changes in HbA1c during the first three-months of anti-TB treatment, but these were not
associated with differences in TB treatment outcomes. Transient hyperglycemia should be considered in TB patients
and needs to be taken into account in planning care and management.
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Background
The risk of tuberculosis (TB) is increased in patients
with diabetes mellitus (DM) [1,2]. The evidence for this
association between DM and TB mainly comes from
industrialized countries, although increasingly the asso-
ciation is being shown in other countries of the world
[3]. The association between the two diseases is import-
ant as DM affects TB treatment outcomes, mainly by
delaying sputum culture conversion, increasing case
fatality and treatment failure, and increasing the risk of
recurrent TB after completion of anti-TB treatment [4].
The global consequences of the interaction between
DM and TB are compounded by the fact that there is a
global epidemic of DM, with prevalent numbers expected
to rise from 370 million in 2012 to over 550 million by
2030 [3]. Iran is similarly affected by a DM epidemic. The
prevalence of DM in the general population aged above
40 years is estimated at 24%, and 10 million DM patients
are estimated to be living now in Iran [5].
It is recognized that blood glucose levels can temporar-
ily increase as a result of infection with TB, which is a
chronic infectious disease [6]. This interaction, and the
rise in blood glucose levels, can result in false positive
diagnoses of DM if blood glucose levels are measured at
the time of registration of TB patients [7,8]. There are
limited data to show whether blood glucose levels stay the
same, decrease or even increase with TB treatment and
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whether there are any associations between these changes
in blood glucose levels and final TB treatment outcomes.
In Iran, we have been assessing blood glucose status
by measurement of glycosylated haemoglobin (HbA1c).
Although there are some challenges with measuring
HbA1c, this is a better marker of blood glucose control
as it provides a measure of blood glucose over a period
of 2? 3 months and is not subject to the rapid swings
that can occur with random and fasting blood glucose
measurements [9]. We therefore decided to examine
HbA1c measurements in new TB patients admitted and
treated at the National Research Institution of Tuberculosis
and Lung Diseases (NRITLD), Masih Daneshvari Hospital,
in Tehran, Iran, at the start and 3-months after TB treat-
ment, and to relate the measurements at these two time
intervals to whether the patients successfully completed
treatment.
Methods
Design and setting
A prospective cohort study of newly TB diagnosed
patients who were admitted at NRITLD was carried out
from May 2012 to May 2013. This institute is one of the
World Health Organization (WHO) collaborating centers
for the Eastern Mediterranean Region (EMRO) and has
been certified as the National Referral Laboratory.
Management of patients
Patients with symptoms and signs suggestive of TB are
referred to NRITLD where a diagnosis of TB is made on
the basis of a positive smear for acid fast bacilli (AFB), a
culture of Mycobacterium tuberculosis, a rapid nucleic
acid amplification test (PCR) or histopathology showing
characteristic pathological findings. Specimens with posi-
tive cultures are also assessed by drug sensitivity testing.
Patients with a diagnosis of TB are treated based on
national and international guidelines for 6 months with
standard drugs (isoniazid, rifampicin, pyrazinamide and
ethambutol for 2 months followed by isoniazid and rifam-
picin for 4 months) or for longer if it is necessary [10]. If
drug-resistance was identified and especially resistance to
isoniazid and rifampicin, the treatment regimen was
changed accordingly and in line with national guidelines.
Baseline laboratory evaluation includes measurement of
random and fasting blood glucose (RBG and FBG), HbA1c,
and other laboratory tests as necessary. HbA1c was mea-
sured using a Nycocard? HbA1c reader on whole blood
with a printed range of values from 4%? 15% (?0.1). All pa-
tients were also tested for HIV using rapid diagnostic tests.
TB patients with HbA1c ≥6.5% are managed in consult-
ation with a nutritionist and referred to Diabetes care for
control of their diabetes.
After discharge from the hospital, treatment is continued
at peripheral health centers and it is also recommended
that patients return to hospital after 3 months for a second
measurement of HbA1c.
For all patients, sputum smear and culture are repeated
at month 5 and at the end of treatment to evaluate
whether there is treatment failure. The outcome of TB
treatment is defined according to WHO guidelines [10].
We considered cured and completed treatment as TB
treatment success and all other outcomes such as failure,
default, transferred out and all-cause mortality as adverse
outcomes.
Patient sample
All adult patients aged above 15 years who were hospital-
ized with newly diagnosed TB were enrolled in the study.
This included all pulmonary TB patients with a positive
sputum smear for acid-fast bacilli (AFB) or a positive
culture of Mycobacterium tuberculosis. It also included all
extra-pulmonary TB patients with positive histopathology,
PCR, AFB smear or culture of a sample obtained from the
site of disease. HbA1c was assessed at the time of regis-
tration and 3-months later, and only patients who had
both these measurements were included in the study
assessment.
Data variables, data sources and data collection
Patient data were obtained from a patient TB register
into a paper-based proforma. Data variables included age,
sex, a new or known diagnosis of DM, smoking status, drug
abuse history, duration of symptoms, type of TB, cavitary
lesion in chest x-ray, grade of sputum smear at base line,
FBG level, HbA1c level, and final TB treatment outcomes.
The grade of sputum smear at base line was defined as:
10? 99 bacilli in 100 high power field = 1+; 1? 10 bacilli in
one high power field = 2+; more than 10 bacilli in one high
power field = 3+; scanty as less than 10 bacilli in 100 high
power fields. These data were single entered into SPSS
version 11.5 [SPSS Inc, Chicago, IL, USA]. All records were
checked for completeness, reliability and precision.
Data analysis and statistics
All demographic and clinical information of TB patients
were transported from SPSS to STATA and analyzed
using Stata, version 12.1 (Statacorp. College Station,
Texas, USA). Patients with TB were divided into four
groups based on the measurements of HbA1c at the two
different time points:
1. Normal- Normal (NN): The patients who had
HbA1c less than 6.5% at two time points. They
were defined as normal
2. Elevated- Normal (EN): The patients who had
HbA1c ≥6.5% at the baseline and at the third
month had <6.5%. They were defined as uncertain
DM status.
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3. Normal- Elevated (NE): The patients who had
HbA1c <6.5% at baseline and after 3 months the
level was more than 6.5%. They were defined as
uncertain DM status.
4. Elevated- Elevated (EE): The patients who had
HbA1c ≥ 6.5% at the beginning and after 3 months
of treatment. They were defined as abnormal and
having DM.
The characteristics and treatment outcome of these four
groups were compared. We eliminated the normal-
elevated group from formal significance testing due to the
limited number of subjects (n = 5) who fell into this group.
Categorical variables were compared by using Chi-square
or Fisher ? s exact test and continuous variables using
ANOVA. All reported p values are two-sided.
Ethics
The study protocol was reviewed and approved by the
NRITLD Scientific and Ethics Committee, Teheran, Iran.
Results
There were 525 new TB patients aged above 15 years
who presented to NRITLD between May 2012 and May
2013. Of these, 208 patients refused to be hospitalized
and were referred to peripheral health centers to receive
treatment, leaving 317 confirmed TB cases with median
age 58 years (inter-quartile range [IQR] 35.5 ? 73.5) that
were admitted to hospital. There were 158 patients who
had HbA1c at baseline and 3 months and 159 patients
who only had HbA1c performed as baseline. The charac-
teristics of these two groups of patients are shown in
Table 1. The two groups were similar except that those
who had both baseline and 3-month HbA1c were younger
than those who had only HbA1c at baseline.
Of 158 patients with HbA1c at baseline and at
3-months, there were 67 (42%) with normal values at both
time points, 5 (3%) with a normal baseline and elevated
3-month value, 49 (31%) with an elevated HbA1c at base-
line and normal value at 3-months and 37 (24%) with
elevated HbA1c at both time points. Thus, 54 (34%) pa-
tients had an uncertain DM status and 24% had DM.
Baseline characteristics of patients with HbA1c done at
baseline and at 3-months are shown in Table 2. There
were some differences between the groups with age, a
known history of DM and prevalence of cavitatory
lesions being highest in patients with DM, and a history
of smoking being highest in those with normal glucose
status. Baseline HbA1c and FBG were highest in those
with confirmed DM.
There were 150 (95%) patients who successfully com-
pleted treatment, with four patients failing treatment,
one lost to follow-up (defaulted) and three having died.
Treatment outcomes in relation to HbA1c levels at
Table 1 Characteristics of TB patients in relation to HbA1c at baseline and at baseline- 3 months
Characteristics All hospitalized patients Patients with HbA1c level at
baseline and at 3-months
Patients with only
baseline HbA1c level
p-value?
Number of patients 317 158 159
Age (Mean ? SD) yrs 55.33 ? 21.04 52.83 ? 21.24 57.82 ? 20.60 0.03
Male gender 163 (51.4%) 77 (48.73%) 86 (54.10%) 0.37
History of smoking 96 (30.3%) 44 (27.85%) 52 (32.70%) 0.40
History of opium use 74 (23.3%) 31 (19.62%) 43 (27%) 0.14
Positive HIV test 17 (5.4%) 5 (3.20%) 12 (7.50%) 0.13
Diabetes mellitus (known) 46 (14.5%) 22 (13.92%) 24 (15.10%) 0.87
Pulmonary tuberculosis 296 (93.4%) 151 (95.57%) 145 (91.20%) 0.20
Symptom duration (months) 3.89 ? 3.18 3.90 ? 3.37 3.88 ? 2.99 0.94
Smear grade of sputum
3+ 114 (36%) 59 (37.34%) 55 (34.6%) 0.79
2+ 32 (10.1%) 13 (8.23%) 19 (11.9%)
1+ 77 (24.3%) 38 (24.05%) 39 (24.5%)
Scanty 44 (13.9%) 24 (15.20%) 20 (12.6%)
Negative 50 (15.8%) 24 (15.20%) 26 (16.4%)
HbA1c (baseline) 7.2 ? 2 7.2 ? 2 7.1 ? 2 0.37
FBG (baseline) 119.1 ? 51.1 119 ? 53 119.3 ? 49.3 0.94
Cavitary lesion 155 (48.9%) 75 (47.50%) 80 (50.3%) 0.65
? Student ? s t-test and x2 test or Fisher exact is used when appropriate.
Abbreviations: TB tuberculosis, HbA1c Glycosylated haemoglobin, SD Standard deviation, HIV human immunodeficiency virus, FBG Fasting blood glucose.
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baseline and at 3-months are shown in Table 3. There
were no significant differences between the different
groups.
Discussion
This study in Iran shows that of patients admitted to hos-
pital with pulmonary or extra-pulmonary TB, just over 40%
had normal HbA1c at baseline and three months, 24% had
DM and the remainder had an uncertain DM status based
on one elevated HbA1c either at baseline or 3-months into
treatment. There were some differences in baseline charac-
teristics between the four groups, with patients who had
definite DM being older and having a higher prevalence of
pulmonary cavitary lesions on chest x-ray and also having
the highest levels of fasting blood glucose and HbA1c.
Treatment outcomes for the whole group were good with
nearly 95% achieving treatment success, and there were no
differences between any of the groups.
The strengths of the study were that unselected con-
secutive patients were enrolled in the study, all patients
had confirmed TB and were treated and monitored in the
same way, and the baseline characteristics, apart from a
slight difference in age, of those with two HbA1c
measurements were similar to those who only had one
baseline measurement. Thus, the findings are probably
representative of all patients admitted to the hospital.
Limitations relate to the fact that the study was carried
out in a referral center, so we cannot claim that our
Table 2 Characteristics of TB patients who had both HbA1c done at baseline and 3-months
Characteristics Patients with HbA1c level at baseline and 3-months* N = 158 p- value?
Normal-Normal Normal? Elevated Elevated-Normal Elevated-Elevated
Number of patients 67 5 49 37
Age (Mean ? SD) yrs 45.3 ? 22.3 58.2 ? 19.8 54.9 ? 21.2 62.9 ? 13.6 0.001
Male gender 34 (50.7%) 2 (40%) 22 (44.9%) 19 (51.4%) 0.78
History of smoking 25 (37.3%) 0 8 (16.3%) 11 (29.7%) 0.05
History of opium use 15 (22.4%) 1 (20%) 8 (16.3%) 7 (18.9%) 0.71
Positive HIV test 3 (4.5%) 0 2 (4.1%) 0 0.43
Diabetes mellitus(known) 1 (1.5%) 0 1 (2%) 20 (54.1%) 0.001
Pulmonary tuberculosis 61 (91%) 5 (100%) 49 (100%) 36 (97.3%) 0.06
Symptom duration (months) 3.64 ? 3.38 5 ? 2.35 4.13 ? 3.72 3.92 ? 3.02 0.75
Smear grade 0.42
3+ 22 (32.8%) 4 (80%) 17 (34.7%) 16 (43.2%)
2+ 7 (10.4%) 0 3 (6.1%) 3 (8.1%)
1+ 13 (19.4%) 0 16 (32.7%) 9 (24.3%)
Scanty 10 (14.9%) 0 9 (18.4%) 5 (13.5%)
Negative 15 (22.4%) 1 (20%) 4 (8.2%) 4 (10.8%)
Cavitary lesion 29 (43.3%) 3 (60%) 19 (38.8%) 24 (64.9%) 0.04
HbA1c (baseline) (%) 5.9 ? 0.4 6.1 ? 0.3 7.1 ? 1 10 ? 2 0.01
FBG (baseline) (mg/dl) 96.1 ? 14.4 118.8 ? 34 104.6 ? 32.5 179.1 ? 73.1 0.001
*Normal level of HbA1c is considered less than 6.5% and elevated level is considered more than 6.5%.
? Student ? s t-test and x2 test or Fisher exact is used when appropriate.
Abbreviations: TB tuberculosis, HbA1c Glycosylated haemoglobin, SD Standard deviation, HIV human immunodeficiency virus, FBG Fasting blood glucose.
Table 3 Relationship of HbA1c levels at baseline and 3-months with final TB treatment outcomes
Outcome of TB treatment Patients with HbA1c level at baseline and 3-months* p-value
Normal-Normal Normal? Elevated Elevated-Normal Elevated-Elevated
Number of patients 67 5 49 37
Number (%) with treatment success 64 (95.5%) 5 (100%) 46 (93.9%) 35 (94.6%) 0.97
Number (%) failing treatment 2 (3%) 0 1 (2%) 1 (2.7%)
Number (%) lost to follow-up (defaulted) 0 0 1 (2%) 0
Number (%) who died 1 (1.5%) 0 1 (2%) 1 (2.7%)
*Normal level of HbA1c is considered less than 6.5% and elevated level is considered more than 6.5%.
Abbreviations: TB tuberculosis, HbA1c Glycosylated haemoglobin, SD Standard deviation, HIV human immunodeficiency virus, FBG Fasting blood glucose.
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findings are representative of all TB patients with or with-
out DM in Iran.
In nearly one third of patients, the high HbA1c level at
baseline was recorded as normal at 3-months. In studies
using fasting blood glucose measurements, the so called
? temporary hyperglycemia? (TH) is well recognized [11]
and several studies have reported glucose intolerance at
the initiation of TB treatment followed by normalization
during treatment [7,12,13]. This may be due to the general
inflammatory status associated with active TB, but if blood
measurements are carried out shortly after registration
and initiation of anti-TB treatment, then this may also be
due to the hyperglycemic effects of rifampicin and isonia-
zid [14]. Whatever the precise reason, this is an important
finding and suggests that a firm diagnosis of DM should
not be made on just one baseline result, whether a fasting
blood glucose or HbA1c is used.
A recent systematic review documented that mortality
and failure rates are increased in patients with DM [4].
Other studies have confirmed these findings of higher
failure rates [15] and higher rates of all-cause mortality
[16,17]. Alisjahbana et al., showed that treatment failure
among DM tuberculosis patients was higher than among
non-DM tuberculosis patients after adjusting for non-
compliance and drug resistance (odds ratio 7.65) [18].
However, this is not always the case. Some studies have
shown no relationship between DM or poor glucose
control and the outcome of TB treatment [19-23]. In a
recent study in China, fasting blood glucose (FBG) was
used to document DM status, and no association was
found between TB treatment outcome and FBG [14]. A
more recent study in a referral centre in India found no
effect of DM on TB treatment outcomes; although there
was a trend towards smear non-conversion at 2-months
[24]. These are similar to the findings of our current
study where we have found no association between glu-
cose status and treatment outcomes. Differences in associ-
ations between DM and TB treatment outcomes may be
due to a number of reasons. There is the power of the
study, especially if the TB program has excellent treatment
outcomes, which means there is a need for larger numbers
of patients to ascertain cause and effect. Then there are is-
sues such as confounders (for example, smoking and HIV
status) and the levels of DM control at the start and dur-
ing anti-TB treatment. All of these require further pro-
spective study with large numbers of patients.
Although we raise questions about the timing of blood
glucose measurement during TB treatment, we believe it is
important to screen for DM near to the start of treatment
if only to intervene and institute appropriate care to reduce
hyperglycemia [25]. Even if this does not have an effect on
TB treatment outcomes, and at present there are few pub-
lished data on whether tight glucose control impacts on
TB treatment outcomes, [6] it is good clinical practice.
Conclusion
In summary, this study shows glycosylated haemoglobin
levels can change during the first 3-months of anti-TB
treatment, but whether glucose status was defined as
normal, uncertain or abnormal this had no effect on TB
treatment outcomes. Further studies are needed to
determine the prevalence and importance of temporary
hyperglycaemia (TH) in other communities.
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